Programs & products

Innate Pharma S.A. announced that IPH 2101 (NN 1975), developed by Novo Nordisk A/S in collaboration with the Company, was administered for the first time in patients suffering from multiple myeloma.

Innate Pharma S.A. has received approval for its phase II trial with IPH 1101 in Type C viral hepatitis.

Innate Pharma S.A. announced it has entered into a in-licensing agreement with Cancer Research Technology (CRT) on novel TLR agent.

Innate Pharma S.A. announced that a set of pharmacological data, from Research to clinical Phase II, of its drug candidate IPH 1101 was presented at the "American Society of Clinical Oncology" annual...

Innate Pharma S.A. today announced two additional clinical trials for its IPH 1101 drug candidate, including the first Innate's trial outside oncology.

Eric Vivier's team at the marseille-luminy Immunology Centre and Innate Pharma researchers announced the development of a new animal model dedicated to studying NK cell activity.

Innate Pharma SA announced today that IPH 2101 (NN 1975), developed by Novo Nordisk A/S in collaboration with Innate Pharma, was administered for the first time in humans.

Innate Pharma SA announced today the commercial launch by its partner, Clinical Data Inc. (NASDAQ: CLDA) of PGxPredict:RITUXIMAB, a pharmacogenetic test that should help physicians to predict the...

Innate Pharma announces worldwide exclusive license with Clinical Data Inc. for the development of a predictive test for response to monoclonal antibody treatment.

Innate pharma has selected a new immuno-modulatory compound for its T gamma-delta platform, IPH 1201. Entering its pre-clinical and pharmaceutical development, IPH 1201 is intended to be developed in...